http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100465666-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-416 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4155 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-416 |
| filingDate | 2001-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2005-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2005-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-100465666-B1 |
| titleOfInvention | Pharmaceutical composition containing YC-1 as effective component |
| abstract | The present invention relates to a pharmaceutical composition containing YC-1 as an active ingredient.n n n YC-1 contained in the pharmaceutical composition of the present invention inhibits the activity of HIF-1 under hypoxic conditions, such as VEGF which induces angiogenesis essential for cancer proliferation and metastasis process and EPO which promotes cancer proliferation Inhibits the expression of hypoxic genes that induce cancer cell survival.n n n Therefore, a pharmaceutical composition containing YC-1 of the present invention as an active ingredient can be used as an active ingredient of an anticancer agent.n n n The pharmaceutical composition containing YC-1 of the present invention as an active ingredient inhibits the attainment of resistance to conventional anticancer treatment in a hypoxic state, thereby preventing other anticancer treatments such as radiation therapy, hormone therapy, chemotherapy and biological response modifiers. It can also be used as an adjuvant.n n n In addition, the pharmaceutical composition containing YC-1 of the present invention as an active ingredient may be used for oxygen formation pathways involving indiscriminate formation of neovascularization, overexpression of VEGF, EPO, HIF-1 and its constituent proteins HIF-1α, and transition metals. It can be used in related diseases. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101068265-B1 |
| priorityDate | 2001-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 291.